Coherus Oncology (CHRS) FCF Margin Growth (1y) (2014 - 2026)
Coherus Oncology (CHRS) FCF Margin Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -89.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1,183.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 26,102.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 869.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 769.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 4,109.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 19,111.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.00 |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -469,347.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -469,347.00 |
| Mar 31, 2026 | -6,827.00 |
| Dec 31, 2025 | -59,031.00 |
| Sep 30, 2025 | 62,424.00 |
| Jun 30, 2025 | 329,082.00 |
| Mar 31, 2025 | -651,362.00 |
| Dec 31, 2024 | 38,412.00 |
| Sep 30, 2024 | -95,190.00 |
| Jun 30, 2024 | 103,511.00 |
| Mar 31, 2024 | 632,402.00 |
| Dec 31, 2023 | 20,641.00 |
| Sep 30, 2023 | 984.00 |
| Jun 30, 2023 | 1,820.00 |
| Mar 31, 2023 | -12,144.00 |
| Dec 31, 2022 | -14,862.00 |
| Sep 30, 2022 | -9,896.00 |
| Jun 30, 2022 | -8,396.00 |
| Mar 31, 2022 | -9,240.00 |
| Dec 31, 2021 | -10,111.00 |
| Sep 30, 2021 | -2,354.00 |